51 results
DEF 14A
NAMS
NewAmsterdam Pharma Company NV
9 May 24
Definitive proxy
4:15pm
the ability to access the proxy materials at www.proxyvote.com. Instructions on how to access the proxy materials over the internet or to request … and medical affairs functions, including marketing, market access, sales, medical science engagement and enterprise operations. Prior to joining
10-Q
2024 Q1
NAMS
NewAmsterdam Pharma Company NV
8 May 24
Quarterly report
4:30pm
and marketing personnel;
the inability of sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future … result in information theft, compromise, or other unauthorized access, data corruption and significant disruption of our business operations
PRE 14A
NAMS
NewAmsterdam Pharma Company NV
29 Apr 24
Preliminary proxy
5:00pm
the ability to access the proxy materials at www.proxyvote.com. Instructions on how to access the proxy materials over the internet or to request … , market access, sales, medical science engagement and enterprise operations. Prior to joining NewAmsterdam Pharma, Mr. Jones most recently served
10-K
2023 FY
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
the needs of patients with high cholesterol due to limited efficacy, an inconvenient injectable administration route and market access restrictions … , there are several limitations with these lines of therapy, such as limited efficacy, route of administration, market access hurdles and side effects. Because PCSK9
10-K
2023 FY
EX-10.4
NAMS
NewAmsterdam Pharma Company NV
28 Feb 24
Annual report
8:00am
processed pursuant to Article 15.1. Personnel or third parties that have access to such personal data shall be bound by confidentiality obligations … , which may include the right to access, rectification, erasure, restriction of processing, objection to processing and portability of such personal data
8-K
EX-1.1
ihpjc
15 Feb 24
NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants
4:18pm
424B5
4f1joh9
15 Feb 24
Prospectus supplement for primary offering
4:15pm
424B5
tkv1hw4
13 Feb 24
Prospectus supplement for primary offering
5:19pm
8-K
EX-99.1
nz0ss7
22 Jan 24
Regulation FD Disclosure
8:01am
8-K
EX-99.2
sodc5k2klaawa38
8 Jan 24
NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors
8:21am
424B3
lm18 r9k9vwf
19 Dec 23
Prospectus supplement
4:36pm
F-3
EX-1.2
j2ffi2eth 98arx
7 Dec 23
Shelf registration (foreign)
4:16pm
F-3
5tgt9iuk yne
7 Dec 23
Shelf registration (foreign)
4:16pm
6-K
EX-99.1
yf6g8amyk0lk4p9m
25 Sep 23
Current report (foreign)
8:10am
424B3
t4vt eftb4ue7fen
15 Aug 23
Prospectus supplement
4:52pm
6-K
EX-99.2
ro5 q54gsh7f
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
6-K
EX-99.1
xb000by0uoz53lz
14 Aug 23
NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer
4:52pm
POS AM
ntzj1m9v1ve1ue
7 Aug 23
Prospectus update (post-effective amendment)
7:56am
6-K
EX-99.2
18wdn1ad qqw
7 Aug 23
Research and development expenses
7:24am
6-K
EX-99.1
o6qj1az
7 Aug 23
Research and development expenses
7:24am